NEW TREATMENT OPTIONS UNDER INVESTIGATION FOR PELVIC ORGAN PROLAPSE Design of next generation meshes using degradable polymers and stem cell based surgical constructs
Pelvic organ prolapse (POP) develops when tissues, pelvic floor muscles and ligaments that support the pelvic organs (bladder, uterus and bowel) are damaged, usually in childbirth. This injury causes the organs to shift, or ‘drop’, into the vagina or event outside of the body. This can lead to debilitating symptoms including poor bladder or bowel control and pain during sex
POP Facts
- 1 in 4 women globally in their 40s live with POP
- 1 in 2 women over 50 years of age live with POP
- $200 million annual cost to the Australian healthcare system
POP is a lifelong, potentially debilitating condition. Despite the high prevalence, there is no cure for POP.
Dr Shayanti Mukherjee, Research Group Head, Translational Tissue Engineering at the with her team at Hudson Institute of Medical Research is developing new ways to prevent and potential cure pelvic organ prolapse (POP). The technology aims to ultimately lead to safer and more effective treatment for women with pelvic organ prolapse (POP) using a woman’s own stem cells to boost the effectiveness of a degradable mesh.
Dr Shayanti Mukherjee specialises in innovative cell-based therapies for pelvic floor disorders and birth trauma injuries.
Dr Mukherjee’s research uses a woman’s own stem cells to create a 3D-printed degradable mesh, promising to avoid the complications that have plagued previous synthetic non-degradable meshes.
“By integrating cutting-edge techniques like electrospinning and 3D printing of materials and cells, I aim to revolutionise maternal urogynaecological health, offering transformative solutions and improving the wellbeing of women affected by this prevalent issue.”
“This research has the potential to revolutionise therapies for pelvic floor regeneration and enable personalised medicine for women,” she said.
“By advancing innovative cell-based therapies, we are on the brink of transforming the landscape of maternal urogynaecological health, promising a brighter and healthier future for women across the globe,” said Dr Mukherjee.
Source: Hudson Institute of Medical Research
-
Misinformation impacts routine vaccines
More significant changes in recent years have been health-related misinformation eroding trust in healthcare professionals, leading to people seeking alternative treatments or avoiding medical advice altogether. This can make it more difficult for healthcare professionals to provide effective treatment and care.
Recent vaccines delivered as part of the COVID-19 response, are having a consequential impact on the uptake of routine vaccines.
Australian Health Journal spoke with Dr Paul Griffin, an Infectious Diseases Physician and Microbiologist at Mater Health, and who has been involved in over 150 clinical trials in the field of infectious disease.
Paul talks about the importance of having reputable sources of information that can used to encourage people to understand what is involved in clinical trials and the roles of vaccines.
-
How I Became an Emergency Physician
Dr Kim Hansen was initially attracted to emergency medicine because of its dynamic and chaotic environment. She enjoyed organising the chaos of the emergency department and working with a variety of patients, from newborn babies to centenarians. Dr Hansen found it fulfilling to help people get better or provide them with assistance and guidance when they couldn’t be cured. The unpredictability of the work was also part of the appeal, and she dedicated herself to developing the skills required to be a good emergency doctor.
-
Jack Lancaster, Evolution Surgical
Continuing the Australian Health Journal, People In Health Care series is Jack Lancaster, the CEO of Evolution Surgical, an Australian owned company established in 2014, specialising in spinal fusion implants and custom instrumentation.
Jack talks about how the company works closely with surgeons to design custom solutions manufactured to surgical requirements, and ultimately, to the benefit of the Australia patient.
